

The National Marine Fisheries Service (NMFS) has adopted the Bureau of Ocean Energy Management's Final EIS No. 20240137 filed 07/26/2024 with the Environmental Protection Agency. The NMFS was a cooperating agency on this project. Therefore, republication of the document is not necessary under Section 1506.3(b)(2) of the CEQ regulations.

*EIS No. 20250002, Draft, FHWA, HI, Honoapi'ilani Highway Improvements Project, Comment Period Ends: 02/24/2025, Contact: Paul La Farga 808-541-2704.*

*EIS No. 20250003, Final, DHS, IBWC, GSA, TX, Proposed Modernization of the Bridge of the Americas Land Port of Entry in El Paso Texas, Review Period Ends: 02/10/2025, Contact: Karla R. Carmichael 817-996-9475.*

*EIS No. 20250004, Draft, USACE, MD, Sparrows Point Container Terminal, Comment Period Ends: 03/21/2025, Contact: Maria N. Teresi 410-962-4252.*

*EIS No. 20250005, Draft, BLM, OR, Bridge Creek Area Allotment Management Plans, Comment Period Ends: 02/24/2025, Contact: Don Rotell 541-573-4400.*

*EIS No. 20250006, Final, USFWS, OR, Elliott State Research Forest Habitat Conservation Plan, Review Period Ends: 02/10/2025, Contact: Shauna Everett 503-231-6949.*

*EIS No. 20250007, Final, USFS, ID, Land Management Plan for the Nez Perce-Clearwater National Forests, Review Period Ends: 02/10/2025, Contact: Sara Daugherty 208-963-4206.*

*EIS No. 20250008, Draft, BLM, AZ, Ranegras Plains Energy Center Project, Comment Period Ends: 02/24/2025, Contact: Derek Eysenbach 602-417-9505.*

*EIS No. 20250009, Draft, NNSA, NM, Draft Site-Wide Environmental Impact Statement for Continued Operation of Los Alamos National Laboratory, Comment Period Ends: 03/11/2025, Contact: Stephen Hoffman 505-665-8980.*

*EIS No. 20250010, Draft, FTA, TX, Austin Light Rail Phase 1 Project, Comment Period Ends: 03/11/2025, Contact: Terence Plaskon 817-978-0573.*

*EIS No. 20250011, Final, TVA, MS, New Caledonia Gas Plant Project, Review Period Ends: 02/10/2025, Contact: Erica McLamb 423-751-8022.*

*EIS No. 20250012, Final, OSM, MT, Spring Creek Mine, Review Period Ends: 02/10/2025, Contact: Marcelo Calle 303-236-2929.*

*Amended Notice:*

*EIS No. 20240148, Draft, APHIS, PRO, Outbreak Response Activities for Highly Pathogenic Avian Influenza Outbreaks in Poultry in the United States and U.S. Territories, Comment Period Ends: 01/17/2025, Contact: Chelsea Bare 515-337-6128.*

Revision to FR Notice published 08/16/2024; APHIS has reopened the comment period to end on 01/17/2025.

Dated: January 6, 2025.

**Mark Austin,**

*Acting Director, NEPA Compliance Division, Office of Federal Activities.*

[FR Doc. 2025-00363 Filed 1-8-25; 8:45 am]

**BILLING CODE 6560-50-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket No. CDC-2025-0003]

#### Meeting of the Advisory Committee on Immunization Practices

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment.

**DATES:** The meeting will be held on February 26, 2025, from 8 a.m. to 5:10 p.m., EST, February 27, 2025, from 8 a.m. to 5 p.m., EST, and February 28, 2025, from 8 a.m. to 11:25 a.m., EST (times subject to change; see the ACIP website for updates: <https://www.cdc.gov/acip>).

Written comments must be received between February 3-17, 2025.

**ADDRESSES:** You may submit comments, identified by Docket No. CDC-2025-0003, by either of the methods listed below. CDC does not accept comments by email.

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments.

- **Mail:** Ms. Stephanie Thomas, ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta, Georgia 30329-4027. Attn: Docket No. CDC-2025-0003.

**Instructions:** All submissions received must include the Agency name and docket number. All relevant comments received in conformance with the <https://www.regulations.gov> suitability policy will be posted without change to <https://www.regulations.gov>, including any personal information provided. For access to the docket to read background documents or comments received, go to <https://www.regulations.gov>.

The meeting will be webcast live via the World Wide Web. The webcast link can be found on the ACIP website at <https://www.cdc.gov/acip>.

#### FOR FURTHER INFORMATION CONTACT:

Stephanie Thomas, Committee Management Specialist, Advisory Committee on Immunization Practices, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta, Georgia 30329-4027. Telephone: (404) 639-8836; Email: [ACIP@cdc.gov](mailto:ACIP@cdc.gov).

#### SUPPLEMENTARY INFORMATION:

**Purpose:** The Advisory Committee on Immunization Practices (ACIP) is charged with advising the Director, Centers for Disease Control and Prevention (CDC), on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under applicable provisions of the Affordable Care Act and section 2713 of the Public Health Service Act, immunization recommendations of ACIP that have been approved by the Director, CDC, and appear on CDC immunization schedules generally must be covered by applicable health plans.

**Matters to be Considered:** The agenda will include discussions on chikungunya vaccines, COVID-19 vaccines, cytomegalovirus (CMV) vaccine, Human papillomavirus (HPV) vaccines, influenza vaccines, meningococcal vaccines, mpox vaccines, pneumococcal vaccines, Respiratory Syncytial Virus (RSV) vaccines for adults, RSV vaccines for maternal and pediatric populations, and Lyme disease. Recommendation votes are scheduled for meningococcal vaccines, chikungunya vaccines, influenza vaccines, and RSV vaccines for adults. Vaccines for Children (VFC) votes are scheduled for influenza and meningococcal vaccines. Agenda items

are subject to change as priorities dictate. For more information on the meeting agenda, visit <https://www.cdc.gov/acip/meetings/index.html>.

**Meeting Information:** The meeting will be webcast live via the World Wide Web. For more information on ACIP, please visit the ACIP website: <https://www.cdc.gov/acip>.

### Public Participation

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on <https://www.regulations.gov>. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near-duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket.

**Written Public Comment:** The docket will be opened to receive written comments February 3–17, 2025. Written comments must be received by February 17, 2025.

**Oral Public Comment:** This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes, including all votes relevant to the ACIP's Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below.

**Procedure for Oral Public Comment:** All persons interested in making an oral public comment at the February 26–28, 2025, ACIP meeting must submit a request at <https://www.cdc.gov/acip/meetings/index.html> between February 3–17, 2025, and no later than 11:59 p.m., EST, February 17, 2025 according to the instructions provided.

If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a random draw to determine the speakers for the

scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by February 19, 2025. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to three minutes, and each speaker may speak only once per meeting.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

### Kalwant Smagh,

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2025–00349 Filed 1–8–25; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Medicare & Medicaid Services

[CMS–7077–N]

### Announcement of the Advisory Panel on Outreach and Education (APOE) Virtual Meeting

**AGENCY:** Centers for Medicare & Medicaid Services (CMS), Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This notice announces the next meeting of the Advisory Panel on Outreach and Education (APOE) (the Panel) in accordance with the Federal Advisory Committee Act. The Panel advises and makes recommendations to the Secretary of the U.S. Department of Health and Human Services (HHS) (the Secretary) and the Administrator of the Centers for Medicare & Medicaid Services (CMS) on opportunities to enhance the effectiveness of consumer education strategies concerning the Health Insurance Marketplace<sup>®</sup>,<sup>1</sup> Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). This meeting is open to the public.

**DATES:**

<sup>1</sup> The Health Insurance Marketplace<sup>®</sup> is a registered service mark of the U.S. Department of Health and Human Services.

**Meeting Date:** Thursday, February 6, 2025 from 12:30 p.m. to 5 p.m. eastern standard time (e.s.t).

**Deadline for Meeting Registration, Presentations, Special Accommodations, and Comments:** Thursday, January 23, 2025 by 5 p.m. e.s.t.

### ADDRESSES:

**Meeting Location:** Virtual. All those who RSVP will receive the link to attend.

**Presentations and Written Comments:** Presentations and written comments should be submitted to: Hailey Gutzmer, Acting Designated Federal Official (DFO), Office of Communications, Centers for Medicare & Medicaid Services, 200 Independence Avenue SW, Mailstop 315D.02, Washington, DC 20201, 410–786–1307, or via email at [APOE@cms.hhs.gov](mailto:APOE@cms.hhs.gov).

**Registration:** Persons wishing to attend this meeting must register at the website <https://CMS-APOE-February2025.rsvpify.com> or by contacting the DFO listed in the **FOR FURTHER INFORMATION CONTACT** section of this notice, by the date listed in the **DATES** section of this notice. Individuals requiring sign language interpretation or other special accommodations should contact the DFO at the address listed in the **ADDRESSES** section of this notice by the date listed in the **DATES** section of this notice.

**FOR FURTHER INFORMATION CONTACT:** Hailey Gutzmer, Acting Designated Federal Official, Office of Communications, Centers for Medicare & Medicaid Services, 200 Independence Avenue SW, Mailstop 315D.02, Washington, DC 20201, 410–786–1307, or via email at [APOE@cms.hhs.gov](mailto:APOE@cms.hhs.gov).

Additional information about the APOE is available at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/APOE>. Press inquiries are handled through the CMS Press Office at (202) 690–6145.

### SUPPLEMENTARY INFORMATION:

#### I. Background and Charter Renewal Information

##### A. Background

The Advisory Panel on Outreach and Education (APOE) (the Panel) is governed by the provisions of the Federal Advisory Committee Act (FACA) (Pub. L. 92–463), as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of federal advisory committees. The Panel is authorized by section 1114(f) of the Social Security Act (the Act) (42 U.S.C. 1314(f)) and section 222 of the Public Health Service Act (42 U.S.C. 217a).